
Sign up to save your podcasts
Or


In this special episode of the Eye Believe Podcast, we bring together six leading experts to discuss newly established consensus guidelines for metastatic uveal melanoma (MUM) surveillance.
Through a modified Delphi panel led by the Collaborative Ocular Oncology Group (COOG), 41 experts from more than 25 centers worked to create standardized surveillance recommendations in an area where high-level evidence remains limited.
Joining us for this conversation are:
Dr. Sunandana Chandra
Dr. Juan Alban
Dr. Meredith McKean
Dr. Jose Lutzky
Dr. Scott Walter
Dr. Sanjay Chandrasekaran
Together, they break down:
-How the Delphi process was used to achieve expert consensus
-Why risk-stratified surveillance (including molecular markers like GEP and PRAME, chromosomal findings, and clinical tumor features) is central to these recommendations
-How standardized monitoring can improve early detection of metastatic disease
-The importance of balancing surveillance benefits with potential risks and patient burden
This panel represents a major step forward in aligning care practices and providing clearer guidance for patients and providers navigating metastatic risk in uveal melanoma.
Whether you are a patient, caregiver, or clinician, this episode offers valuable insight into how expert collaboration is shaping the future of uveal melanoma care.
By A Cure In Sight5
1515 ratings
In this special episode of the Eye Believe Podcast, we bring together six leading experts to discuss newly established consensus guidelines for metastatic uveal melanoma (MUM) surveillance.
Through a modified Delphi panel led by the Collaborative Ocular Oncology Group (COOG), 41 experts from more than 25 centers worked to create standardized surveillance recommendations in an area where high-level evidence remains limited.
Joining us for this conversation are:
Dr. Sunandana Chandra
Dr. Juan Alban
Dr. Meredith McKean
Dr. Jose Lutzky
Dr. Scott Walter
Dr. Sanjay Chandrasekaran
Together, they break down:
-How the Delphi process was used to achieve expert consensus
-Why risk-stratified surveillance (including molecular markers like GEP and PRAME, chromosomal findings, and clinical tumor features) is central to these recommendations
-How standardized monitoring can improve early detection of metastatic disease
-The importance of balancing surveillance benefits with potential risks and patient burden
This panel represents a major step forward in aligning care practices and providing clearer guidance for patients and providers navigating metastatic risk in uveal melanoma.
Whether you are a patient, caregiver, or clinician, this episode offers valuable insight into how expert collaboration is shaping the future of uveal melanoma care.

7,979 Listeners